13F Holdings
中文EN

NYMXF NYMOX PHARMACEUTICAL CORP IFRS

In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 1018735 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY49.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-701.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,135.9%
Debt / equity—
Current ratio0.09x
Interest coverage-18.95x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-295.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue—$0$0$0$5,000
Cost of revenue—$0$0$0$4,000
Gross profit—$0$0$0$1,000
R&D expense$3.28M$3.99M$3.77M$6.66M$8.12M
SG&A expense$1.00M$4.36M$2.88M$5.85M$3.60M
Operating income-$4.28M-$8.35M-$6.65M-$12.50M-$11.72M
Interest expense$226,000$58,000$28,000$20,000-$30,000
Pretax income-$4.49M-$8.84M-$6.58M-$12.54M-$11.74M
Income tax$0$0$0$0$0
Net income-$4.49M-$8.84M-$6.58M-$12.54M-$11.74M
EPS (basic)-0.05-0.10-0.07-0.15-0.16
EPS (diluted)————-0.16
Balance sheet
Cash & equivalents$74,000$70,000$1.40M$830,000$3.61M
Receivables$0$0$0$0$0
Inventory——$0$34,000$34,000
Current assets$653,000$625,000$1.46M$1.04M$3.89M
PP&E, netmay include right-of-use assets (IFRS)$1,000$2,000$10,000$22,000$28,000
Total assets$654,000$627,000$1.62M$1.44M$4.34M
Current liabilities$7.43M$3.80M$2.11M$1.79M$1.97M
Total liabilities$7.43M$3.80M$2.11M$1.95M$2.20M
Shareholders' equity-$6.78M-$3.17M-$482,000-$506,000$2.15M
Shares outstanding94.54M93.54M90.52M85.55M—
Cash flow statement
Operating cash flow-$2.60M-$4.06M-$5.21M-$9.82M-$10.04M
Capital expenditure$0$3,000$0$6,000$13,000
Free cash flow-$2.60M-$4.06M-$5.21M-$9.83M-$10.05M
Investing cash flow$0-$3,000$0-$6,000-$13,000
Financing cash flow$2.60M$2.73M$5.78M$7.04M$8.42M
Stock-based compensation$671,000$3.36M$593,000$2.60M$1.75M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.